Invitrogen Corporation Receives Approval from Health Canada for System to Help Determine Organ Transplant Compatibility

CARLSBAD, Calif.--(BUSINESS WIRE)--Invitrogen, a division of Life Technologies Corporation (NASDAQ:LIFE), today announced that its DynaChip® HLA Antibody Analysis System has received approval from Health Canada’s Medical Device Bureau for the detection and identification of antibodies to human leukocyte antigen (HLA) markers, which is an essential step in determining the compatibility of organ donors.
MORE ON THIS TOPIC